Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Ongoing Phase 3 studies will determine whether these biochemical and histologic improvements translate into long-term clinical benefit, positioning FGF21 analogues as cornerstone therapies for metabolic disease
This vulnerability was not due to decreased GPX4 expression (Supplementary Fig
Funding This work was supported by grants from the National Natural Science Foundation of China (NSFC Numbers 81672800, 81603009, 81673020, 81802632, and 82173830), Natural Science Foundation of Shaanxi (2020JQ-445), and the Key Research and Development Program of Shaanxi Province (2021SF-207, 2021SF-223, and 2022ZDLSF05-19)
TAC, Total Antioxidant Capacity
O., Fieger-Bschges, H., Ruus, P., Nowak, H., Riethmller-Winzen, H., Peukert, M., & Blume, H
